ESMO Congress 2021
![Delegates venue welcome](/var/esmo/storage/images/media/esmo-daily-reporter/images/generic-pictures-stock/delegates-venue-welcome/8875239-1-eng-GB/delegates-venue-welcome_i770.png)
From empiric testing to rational design: two decades of progress in phase I trials
Ensuring equitable access to innovative treatments is now the major challenge in oncology, says Prof. Alex Adjei
![ESMO Congress 2021](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2021/8731141-3-eng-GB/esmo-congress-2021.jpg)
Translating research ideas into patient benefits
Investigations are time-consuming and expensive, so greater public funding is needed, according to Prof. George Coukos
![ESMO Congress 2021](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2021/8731141-3-eng-GB/esmo-congress-2021.jpg)
Precision oncology is the goal today, not a simple slogan
Prof. Lisa Licitra: “Truly pursuing precision medicine means pushing the boundaries of patient selection using molecular biology and artificial intelligence on all big data, not just molecular information”
![The right to be forgotten reduces financial toxicity in cancer survivors](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2021/covid-19-and-cancer/the-right-to-be-forgotten-reduces-financial-toxicity-in-cancer-survivors/8866308-3-eng-GB/the-right-to-be-forgotten-reduces-financial-toxicity-in-cancer-survivors_i770.png)
The right to be forgotten reduces financial toxicity in cancer survivors
Reduced access to insurance, bank loans and mortgages makes financial constraints continue long after cancer has been treated
![CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2021/drug-development/checkmate-743-reinforces-the-role-of-immunotherapy-in-first-line-mesothelioma/8865408-5-eng-GB/checkmate-743-reinforces-the-role-of-immunotherapy-in-first-line-mesothelioma_i770.png)
CheckMate 743 reinforces the role of immunotherapy in first-line mesothelioma
Nearly 1 in 4 patients with pleural malignancy continue to benefit from nivolumab plus ipilimumab at 3 years
![More than one in six cancer patients experience long-term effects of COVID-19](/var/esmo/storage/images/esmo-daily-reporter/esmo-congress-2021/drug-development/more-than-one-in-six-cancer-patients-experience-long-term-effects-of-covid-19/8866524-2-eng-GB/more-than-one-in-six-cancer-patients-experience-long-term-effects-of-covid-19_i770.jpg)
More than one in six cancer patients experience long-term effects of COVID-19
OnCOVID study reveals that respiratory symptoms, fatigue and cognitive/psychological dysfunction persist after acute Sars-CoV-2 infection, with an impact on survival and oncological outcomes after recovery